ERBB2 and breast cancer: Considering a potential effect in preventing the development of BrM, a phase III trial of lapatinib plus capecitabine vs capecitabine alone in patients with HER2+ advanced BC who were previously treated with an anthracycline, taxane, and trastuzumab was developed.